



Liste modèle des médicaments essentiels

Alfacalcidol

Section	Indications
Medicines for endocrine disorders Oral > Liquid: 2 µg per mL Oral > Solid > capsule: 0.25 µg; 1 µg	Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport

Bromocriptine

Section	Indications
Medicines for disorders of the pituitary hormone system Therapeutic equivalent to cabergoline pour	Other specified benign neoplasm of endocrine glands

Cabergoline

Section	Indications
Medicines for disorders of the pituitary hormone system Oral > Solid > tablet: 0.5 mg; 1 mg	Other specified benign neoplasm of endocrine glands

Calcitriol

Section	Indications
Medicines for endocrine disorders Oral > Solid > capsule: 0.25 µg; 0.5 µg	Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport

Canagliflozin

Section	Indications
Oral hypoglycaemic agents Therapeutic equivalent to empagliflozin pour	Type 2 diabetes mellitus

Carbimazole

Section	Indications
Thyroid hormones and antithyroid medicines Therapeutic equivalent to methimazole pour	Thyrotoxicosis

Dapagliflozin

Section	Indications
Oral hypoglycaemic agents	Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus

Diazoxide

Section	Indications
Medicines for hypoglycaemia	Persistent hyperinsulinaemic hypoglycaemia of infancy
Oral > Liquid: 50 mg per mL	
Oral > Solid: 50 mg	

Empagliflozin

Section	Indications
Oral hypoglycaemic agents	Type 2 diabetes mellitus
Oral > Solid: 10 mg; 25 mg	

Estradiol

Section	Indications
Estrogens	Gonadotropin deficiency
Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg	Hypopituitarism
	Turner syndrome

Fludrocortisone

Section	Indications
Adrenal hormones and synthetic substitutes	Adrenocortical insufficiency
Oral > Solid: 100 µg (acetate)	

Glibenclamide

Section	Indications
Oral hypoglycaemic agents	Type 2 diabetes mellitus
Oral > Solid: 5 mg; 2.5 mg	

Gliclazide

Section	Indications
Oral hypoglycaemic agents Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release	Type 2 diabetes mellitus

Glucagon

Section	Indications
Medicines for hypoglycaemia Parenteral > General injections > unspecified: 1 mg per mL	Hypoglycaemia in the context of diabetes

Hydrocortisone

Section	Indications
Adrenal hormones and synthetic substitutes Oral > Solid: 5 mg; 10 mg; 20 mg	Adrenocortical insufficiency

Insulin (analogue, long-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (human, intermediate-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (human, short-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin analogues

Section	Indications
Insulins	Type 1 diabetes mellitus
Not specified	Type 2 diabetes mellitus

Insulin degludec

Section	Indications
Insulins	Therapeutic equivalent to insulin glargine pour
Parenteral > General injections > SC: 100 units per mL	Type 1 diabetes mellitus
	Therapeutic equivalent to insulin (analogue, long-acting) pour
	Type 1 diabetes mellitus
	Therapeutic equivalent to insulin (analogue, long-acting) pour
	Type 2 diabetes mellitus

Insulin detemir

Section	Indications
Insulins	Therapeutic equivalent to insulin glargine pour
	Type 1 diabetes mellitus
	Therapeutic equivalent to insulin (analogue, long-acting) pour
	Type 1 diabetes mellitus
	Therapeutic equivalent to insulin (analogue, long-acting) pour
	Type 2 diabetes mellitus

Insulin glargine

Section	Indications
Insulins	Type 1 diabetes mellitus
Parenteral > General injections > SC: 100 units per mL	Therapeutic equivalent to insulin (analogue, long-acting) pour
	Type 1 diabetes mellitus
	Therapeutic equivalent to insulin (analogue, long-acting) pour
	Type 2 diabetes mellitus

Ketoconazole

Section	Indications
Medicines for endocrine disorders Oral > Solid > tablet: 200 mg	Cushing syndrome

Levothyroxine

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)	Hypothyroidism

Liraglutide

Section	Indications
Medicines for endocrine disorders Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen	Obesity

Lugol's solution

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)	Thyrotoxicosis

Medroxyprogesterone acetate

Section	Indications
Progestogens Oral > Solid: 5 mg	Excessive menstruation with irregular cycle

Metformin

Section	Indications
Oral hypoglycaemic agents Oral > Solid: 500 mg (hydrochloride)	Type 2 diabetes mellitus

Methimazole

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Solid: 5 mg; 10 mg; 20 mg	Thyrotoxicosis

Norethisterone

Section	Indications
Progestogens Oral > Solid: 5 mg	Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate pour Excessive menstruation with irregular cycle

Octreotide

Section	Indications
Medicines for disorders of the pituitary hormone system Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)	Acromegaly or pituitary gigantism

Phosphorus

Section	Indications
Medicines for endocrine disorders Oral > Other: 500 mg in sachet (elemental phosphorus) granules Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)	Hypophosphataemic rickets

Potassium iodide

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Solid: 60 mg	Thyrotoxicosis

Propylthiouracil

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Solid: 50 mg	Thyrotoxicosis

Simvastatin

Section	Indications
Medicines for endocrine disorders Oral > Solid: 20 mg	Polycystic ovary syndrome

Somatropin

Section	Indications
Medicines for endocrine disorders Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge	Hypoglycaemia without associated diabetes

Testosterone

Section	Indications
Androgens Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)	Testicular dysfunction or testosterone-related disorders

Tolbutamide

Section	Indications
Oral hypoglycaemic agents Oral > Solid: 500 mg	Type 2 diabetes mellitus

Zoledronic acid

Section	Indications
Medicines for endocrine disorders Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Osteogenesis imperfecta